Meglitinide: Difference between revisions
m Protected "Meglitinide": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
The '''meglitinide''' class of drugs treat [[diabetes type 2]] by blocking the [[potassium channels]] in [[beta cells]], which closes the [[Adenosine triphosphate|ATP]]-dependent potassium channels and opens the cells' [[calcium channels]]. The resulting calcium influx causes the cells to secrete [[insulin]]. | The '''meglitinide''' class of drugs treat [[diabetes type 2]] by blocking the [[potassium channels]] in [[beta cells]], which closes the [[Adenosine triphosphate|ATP]]-dependent potassium channels and opens the cells' [[calcium channels]]. The resulting calcium influx causes the cells to secrete [[insulin]]. | ||
| Line 12: | Line 12: | ||
== Side-effects == | == Side-effects == | ||
Side effects include weight gain and [[hypoglycemia]]. While the potential for hypoglycemia is less than for those on [[sulfonylurea]]s, it is still a serious potential side effect that can be life-threatening. Patients on this medication should know the signs and symptoms of [[hypoglycemia]] and appropriate [[Hypoglycemia#Reversing_acute_hypoglycemia|action]] to take. | Side effects include weight gain and [[hypoglycemia]]. While the potential for hypoglycemia is less than for those on [[sulfonylurea]]s, it is still a serious potential side effect that can be life-threatening. Patients on this medication should know the signs and symptoms of [[hypoglycemia]] and appropriate [[Hypoglycemia#Reversing_acute_hypoglycemia|action]] to take. | ||
{{Oral_hypoglycemics}} | {{Oral_hypoglycemics}} | ||
[[Category:Meglitinides]] | [[Category:Meglitinides]] | ||
Latest revision as of 17:17, 9 August 2012
|
WikiDoc Resources for Meglitinide |
|
Articles |
|---|
|
Most recent articles on Meglitinide Most cited articles on Meglitinide |
|
Media |
|
Powerpoint slides on Meglitinide |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Meglitinide at Clinical Trials.gov Clinical Trials on Meglitinide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Meglitinide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Meglitinide Discussion groups on Meglitinide Patient Handouts on Meglitinide Directions to Hospitals Treating Meglitinide Risk calculators and risk factors for Meglitinide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Meglitinide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
The meglitinide class of drugs treat diabetes type 2 by blocking the potassium channels in beta cells, which closes the ATP-dependent potassium channels and opens the cells' calcium channels. The resulting calcium influx causes the cells to secrete insulin.
Drugs
The main branded drug in the meglitinide class is Novo Nordisk's repaglinide (Prandin), which gained FDA approval in 1997. Another type of drug in this class is nateglinide (Starlix).
These drugs should be taken 0-30 minutes prior to eating. Follow the instructions given to you by your physician/nurse.
Side-effects
Side effects include weight gain and hypoglycemia. While the potential for hypoglycemia is less than for those on sulfonylureas, it is still a serious potential side effect that can be life-threatening. Patients on this medication should know the signs and symptoms of hypoglycemia and appropriate action to take.
Template:Oral hypoglycemics Template:WH Template:WikiDoc Sources